Intervention

INSULIN GLULISINE

ClinicalTrials.gov intervention label

Clinical trials7

Recruiting0

Common conditions2

Lead sponsors shown1

Clinical trials

7 shown

Apidra Children & Adolescents StudyNCT01202474 · 2011-05-01

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering DrugsNCT01203111 · 2010-12-01

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes MellitusNCT01204593 · 2010-11-01

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)NCT01212913 · 2010-08-01

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.NCT01122979 · 2010-07-01

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative StudyNCT01121835 · 2010-02-01

Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral NutritionNCT01081938 · 2010-02-01

Common conditions

Diabetes Mellitus, Type 25 Diabetes Mellitus, Type 12

Leading sponsors

Trial status mix

COMPLETED6

TERMINATED1

Phase mix

PHASE47

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.